Veracyte (VCYT) Expected to Post Quarterly Earnings on Wednesday

Veracyte (NASDAQ:VCYT) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.4103 per share and revenue of $147.16 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Veracyte (NASDAQ:VCYT) last posted its earnings results on Thursday, July 30th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The company had revenue of $150.32 million during the quarter, compared to the consensus estimate of $144.59 million. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 EPS. On average, analysts expect Veracyte to post $1.32 EPS for the current fiscal year and $1.50 EPS for the next fiscal year.

Veracyte Trading Up 4.3%

Shares of VCYT stock opened at $50.28 on Wednesday. The firm has a 50-day moving average of $43.86 and a 200-day moving average of $42.80. Veracyte has a one year low of $29.45 and a one year high of $60.91.

Insider Buying and Selling at Veracyte

In related news, Director Jens Holstein sold 5,000 shares of Veracyte stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $40.95, for a total value of $204,750.00. Following the sale, the director owned 27,471 shares of the company’s stock, valued at approximately $1,124,937.45. The trade was a 15.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Muna Bhanji sold 1,864 shares of the stock in a transaction on Monday, October 19th. The stock was sold at an average price of $43.70, for a total value of $81,456.80. Following the transaction, the director owned 40,854 shares of the company’s stock, valued at $1,785,319.80. The trade was a 4.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,759 shares of company stock valued at $1,388,904 in the last three months. 1.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

VCYT has been the subject of a number of recent analyst reports. Morgan Stanley reduced their price objective on shares of Veracyte from $47.00 to $44.00 and set an “underweight” rating for the company in a research report on Tuesday, August 4th. Stephens decreased their price objective on shares of Veracyte from $68.00 to $55.00 and set an “overweight” rating for the company in a research note on Tuesday, August 4th. Wall Street Zen cut shares of Veracyte from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 10th. Zacks Research downgraded Veracyte from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Finally, Piper Sandler decreased their price target on Veracyte from $66.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Veracyte currently has an average rating of “Moderate Buy” and an average price target of $55.78.

Veracyte Company Profile

Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests are designed to provide additional molecular information from patient samples, often helping reduce uncertainty and support more personalized care.

The company’s portfolio includes Afirma tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests for breast cancer. Veracyte also develops and commercializes additional genomic assays intended for use across various cancer types and clinical settings.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte primarily serves the U.S.